Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Short-term Investments (2020 - 2025)

Silence Therapeutics' Short-term Investments history spans 4 years, with the latest figure at $73.8 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 14.05% year-over-year to $73.8 million; the TTM value through Dec 2025 reached $73.8 million, up 14.05%, while the annual FY2025 figure was $73.8 million, 14.05% up from the prior year.
  • Short-term Investments for Q4 2025 was $73.8 million at Silence Therapeutics, up from $20.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $73.8 million in Q4 2025 and bottomed at $20.2 million in Q3 2025.
  • The 3-year median for Short-term Investments is $68.2 million (2024), against an average of $56.6 million.
  • The largest annual shift saw Short-term Investments soared 75.11% in 2024 before it increased 14.05% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $37.0 million in 2023, then skyrocketed by 75.11% to $64.7 million in 2024, then increased by 14.05% to $73.8 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Short-term Investments are $73.8 million (Q4 2025), $20.2 million (Q3 2025), and $72.4 million (Q2 2025).